Navigation Links
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Date:6/2/2009

NF-alpha therapy approved by the FDA for the treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms in patients who have an inadequate response to conventional therapy. During the past decade, REMICADE has also become the first and only anti-TNF-alpha therapy approved by the FDA for the treatment of moderately to severely active ulcerative colitis, in patients with an inadequate response to conventional therapy, a related inflammatory bowel disease. REMICADE is also approved for the treatment of pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapies.

The SONIC study was supported by Centocor Ortho Biotech, Inc.

About SONIC

SONIC was a multicenter, Phase 3b, randomized, double-blind, controlled clinical trial designed to compare the efficacy and safety of REMICADE monotherapy, azathioprine monotherapy and combination therapy with the 2 drugs in patients with moderately to severely active Crohn's disease who were naive to immunomodulator and biologic therapy. A total of 508 patients from the U.S., Europe and Israel were enrolled in the study and were randomized into three groups; 170 patients received azathioprine less than or equal to 2.5 mg/kg/day and placebo infusions, 169 patients received REMICADE 5 mg/kg infusions at weeks 0, 2, 6 and every 8 weeks thereafter with placebo capsules and 169 patients received REMICADE 5 mg/kg and azathioprine less than or equal to 2.5 mg/kg/day at week 26. The primary endpoint of SONIC was to assess the induction of steroid-free remission at week 26. Patients completing treatment through week 30, and who, in the opinion of the investigator, may benefit from continued treatment, entered into the study extension beginning at week 30 through week 50.

SONIC previously demonstrated the effect of REMICADE therapy on steroid-free remiss
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/24/2015)... Mass. , April 24, 2015  Blueprint ... BLU-554, a selective and potent inhibitor of fibroblast ... activity in models of hepatocellular carcinoma (HCC) that ... therapeutic candidate, BLU-554 induced complete tumor regression in ... an FGFR4-activating ligand at the highest dose levels. ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3BeaconMedaes launches new Zone Valve Box Assembly 2
... REDWOOD CITY, Calif., Aug. 17 Cardica, Inc. (Nasdaq: ... Intuitive Surgical, Inc. have entered into a license agreement ... intellectual property, which relates to tissue cutting, stapling and ... to the license agreement, Cardica and Intuitive may also ...
... (Nasdaq: BMRN ) announced today that it ... company developing enzyme replacement therapies (ERT) for the treatment ... ZC-701, a novel fusion of insulin-like growth factor 2 ... Under the terms of the agreement, BioMarin ...
Cached Medicine Technology:Cardica and Intuitive Surgical Enter Into License Agreement 2Cardica and Intuitive Surgical Enter Into License Agreement 3BioMarin Acquires ZyStor Therapeutics, Inc. 2BioMarin Acquires ZyStor Therapeutics, Inc. 3BioMarin Acquires ZyStor Therapeutics, Inc. 4BioMarin Acquires ZyStor Therapeutics, Inc. 5
(Date:4/24/2015)... 2015 Anchor Health Administrators (Anchor), specialists ... today announced their exclusive agreement with LTC Solutions for ... Insurance distribution partner. , Anchor has more than 18 ... benefits for associations, and is currently the designated advocate ... Term Care Insurance member benefit. , “I am very ...
(Date:4/24/2015)... Olive Fertility Centre is proud to ... co-director, has been honoured for his pioneering work in ... Hope Gala. , “We are very pleased to ... has been at the forefront of fertility research and ... Executive Director of Fertile Futures--a Canadian non-profit organization that ...
(Date:4/24/2015)... With years of experience providing consumer ... to be partnered with a veterinary college where veterinary ... This partnership has brought new payment options for families ... providing an in-house payment plan for many years, the ... to increase financing options available to avoid having to ...
(Date:4/24/2015)... National Access Cannabis (NAC), ... to medical cannabis, is taking a leadership role in ... patients. , NAC is the first to back mdBriefCase ... grant, NAC will be providing 300 healthcare professionals with ... to help Canadians gain safe and responsible access to ...
(Date:4/24/2015)... Opera ” was featured on NewsWatch as part of its ... products available to consumers. Andrew Tropeano, a technology expert and ... viewers how this is the fastest way to surf the ... be in existence. But each web browser is slightly different ... Celebrating their 20th anniversary this year, Opera connects over 350 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:University of Missouri Veterinary Medical Teaching Hospital Teams with UGA 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:A Web Browser That Connects over 350 Million People was Featured on NewsWatch Television 2
... ValueOptions(R), Inc., the nation,s largest independent behavioral ... entered into an agreement with CareIntegra to provide ... its core product offerings. (Logo: ... CareIntegra and ValueOptions(R) will collaborate to develop and ...
... Va., Jan. 7 CEL-SCI Corporation (NYSE Alternext ... announced today the initiation of a definitive study of ... the long-lasting beneficial effects on animals with the disease. ... a large pharmaceutical company which is evaluating the possibility ...
... ORLEANS, Jan. 7 Jones Walker is pleased to announce ... an Order of the British Crown that has been in ... in the New Orleans office of Jones Walker, was recently ... Hamilton, a Partner in the firm,s Mobile and Washington offices, ...
... Virginia, January 7 Ekahau Inc., a leading,provider ... announced,that after a competitive bid process it was ... to provide the Ekahau Real Time,Location System (RTLS) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081014/324879-a ) , ...
... shownOAKBROOK TERRACE, Ill., Jan. 7 Even though nurses ... study published in the January 2009 issue of ... shows that nurses often are not included when ... such a hands-on role at the bedside of their ...
... Atlanta-based Billian Publishing, Inc.,owners of Billian,s HealthDATA, announced ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070925/BILLIANSLOGO ) ... founded in 1989 just as the information technology,industry ... Since then, new,and established companies have contracted with ...
Cached Medicine News:Health News:ValueOptions(R) Enters Agreement with CareIntegra to Provide Integrated Health Services 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 2Health News:CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine 3Health News:Jones Walker Attorneys Named to Positions in Order of British Crown 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 2Health News:Ekahau Selected to Provide RTLS to University HealthSystem Consortium 3Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 2Health News:Study Finds Failure to Include Nurses in Process of Admitting Errors to Patients, Families 3Health News:Billian Publishing, Inc. Announces Acquisition of Porter Research 2
Stainless steel construction to withstand sterilization modalities (EtO, Steris, and Sterrad) Wide angle of view...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Superior imaging through a 410,000 pixel CCD, unseen color replication from a digital signal processor in the scope, and the added benefit of four way tip deflection make the TF410 a superior choice ...
The edge-to-edge clarity of the laparoscopes provides excellent image definition.Even small structures are easily recognized due to the optimal depth of focus. The outstanding optical quality provide...
Medicine Products: